HilleVax Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. HilleVax Inc. is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-147.27M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.62 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -51.86% |
| Return on Assets (Trailing 12 Months) | -41.45% |
| Current Ratio (Most Recent Fiscal Quarter) | 25.32 |
| Quick Ratio (Most Recent Fiscal Quarter) | 25.32 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.01 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.47 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.15 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 50.14M |
| Free Float | 37.66M |
| Market Capitalization | $93.26M |
| Average Volume (Last 20 Days) | 0.21M |
| Beta (Past 60 Months) | 0.78 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 24.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.42% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |